尼日尔轮状病毒疫苗2岁内及针对不同流行株的效力:随机对照试验延长随访
该研究为尼日尔健康婴儿的随机对照试验延长随访,评估热稳定口服轮状病毒疫苗Rotasiil对严重轮状病毒胃肠炎的2年效力及不同基因型效力。结果显示疫苗在1岁内效力显著,至2岁总体效力仍显著,但第二年的差异无统计学意义,且对多种流行株的效力与总体一致。
要点
- Rotasiil在1岁内对SRVGE效力60.3%(95%CI 43.6%–72.1%)。
- 至2岁总体效力54.7%(95%CI 38.1%–66.8%),第二年未达统计学显著。
- 疫苗对多种轮状病毒基因型的效力与总体效力一致。
核心结论
- Rotasiil在约2年延长随访期内对婴儿严重轮状病毒胃肠炎提供保护,1岁内保护显著,对流行株变化亦有效。
研究设计与样本
- 随机对照试验延长随访,婴儿按1:1随机接受3剂Rotasiil或安慰剂,约6、10、14周龄接种。
- 符合方案效力分析纳入3508名婴儿,首剂平均年龄6.5周,49%为男性。
主要发现
- 1岁内疫苗组和安慰剂组SRVGE发病率分别为3.96和9.98例/100人年,效力60.3%(95%CI 43.6%–72.1%)。
- 至2岁疫苗组和安慰剂组SRVGE发病率分别为2.13和4.69例/100人年,效力54.7%(95%CI 38.1%–66.8%)。
- 第二年效力差异无统计学意义。
- 至2岁疫苗接种每100儿童年预防2.56例SRVGE。
- 按各轮状病毒基因型估计的SRVGE效力与总体保护效力一致。
临床怎么用
- 可在资源有限地区将Rotasiil纳入婴儿免疫规划,以降低1岁内疾病负担和死亡风险。
- 疫苗对多种流行株有效,支持持续接种以应对轮状病毒株变化。
局限性
- 因合并口服脊灰疫苗比例低,结果对常规同时接种脊灰疫苗的场景外推性有限。
- 第二年事件数少,评估该期效力的把握度有限。
- 安慰剂儿童在研究疫苗接收时被删失可能引入偏倚。
- 基于Vesikari评分的严重度评分适配欠佳,该评分原为高父母识字率环境设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus vaccination is recommended in all countries to reduce the burden of diarrhea-related morbidity and mortality in children. In resource-limited settings, rotavirus vaccination in the national immunization program has important cost implications, and evidence for protection beyond the first year of life and against the evolving variety of rotavirus strains is important. We assessed the extended and strain-specific vaccine efficacy of a heat-stable, affordable oral rotavirus vaccine (Rotasiil, Serum Institute of India, Pune, India) against severe rotavirus gastroenteritis (SRVGE) among healthy infants in Niger. METHODS AND FINDINGS: From August 2014 to November 2015, infants were randomized in a 1:1 ratio to receive 3 doses of Rotasiil or placebo at approximately 6, 10, and 14 weeks of age. Episodes of gastroenteritis were assessed through active and passive surveillance and graded using the Vesikari score. The primary endpoint was vaccine efficacy of 3 doses of vaccine versus placebo against a first episode of laboratory-confirmed SRVGE (Vesikari score ≥ 11) from 28 days after dose 3, as previously reported. At the time of the primary analysis, median age was 9.8 months. In the present paper, analyses of extended efficacy were undertaken for 3 periods (28 days after dose 3 to 1 year of age, 1 to 2 years of age, and the combined period 28 days after dose 3 to 2 years of age) and by individual rotavirus G type. Among the 3,508 infants included in the per-protocol efficacy analysis (mean age at first dose 6.5 weeks; 49% male), the vaccine provided significant protection against SRVGE through the first year of life (3.96 and 9.98 cases per 100 person-years for vaccine and placebo, respectively; vaccine efficacy 60.3%, 95% CI 43.6% to 72.1%) and over the entire efficacy follow-up period up to 2 years of age (2.13 and 4.69 cases per 100 person-years for vaccine and placebo, respectively; vaccine efficacy 54.7%, 95% CI 38.1% to 66.8%), but the difference was not statistically significant in the second year of life. Up to 2 years of age, rotavirus vaccination prevented 2.56 episodes of SRVGE per 100 child-years. Estimates of efficacy against SRVGE by individual rotavirus genotype were consistent with the overall protective efficacy. Study limitations include limited generalizability to settings with administration of oral polio virus due to low concomitant administration, limited power to assess vaccine efficacy in the second year of life owing to a low number of events among older children, potential bias due to censoring of placebo children at the time of study vaccine receipt, and suboptimal adapted severity scoring based on the Vesikari score, which was designed for use in settings with high parental literacy. CONCLUSIONS: Rotasiil provided protection against SRVGE in infants through an extended follow-up period of approximately 2 years. Protection was significant in the first year of life, when the disease burden and risk of death are highest, and against a changing pattern of rotavirus strains during the 2-year efficacy period. Rotavirus vaccines that are safe, effective, and protective against multiple strains represent the best hope for preventing the severe consequences of rotavirus infection, especially in resource-limited settings, where access to care may be limited. Studies such as this provide valuable information for the planning of national immunization programs and future vaccine development. TRIAL REGISTRATION: ClinicalTrials.gov NCT02145000.
引用
- Isanaka S, Langendorf C, McNeal MM, et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial. PLoS Med. 2021. PMID: 34214095. doi:10.1371/journal.pmed.1003655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。